Table 4.
Mortality rates at 30 days and 2 years
| 30-day mortality | 2-year mortality | |||||||
|---|---|---|---|---|---|---|---|---|
| L-VVI rate (%) | TV-VVI rate (%) | Unadjusted OR (confidence interval) |
Adjusted OR (confidence interval) |
L-VVI rate (%) | TV-VVI rate (%) | Unadjusted HR (confidence interval) |
Adjusted HR (confidence interval) |
|
| COPD | 5.84 | 5.69 | 1.031 (0.795–1.339) |
0.928 (0.710–1.215) |
42.53 | 40.64 | 1.110 (1.003–1.229) |
1.048 (0.944–1.164) |
| Diabetes | 4.72 | 4.50 | 1.053 (0.816–1.358) |
0.871 (0.671–1.131) |
37.05 | 33.57 | 1.175 (1.072–1.288) |
1.041 (0.946–1.146) |
| ȃDiabetes with high aDCSI | 5.92 | 5.84 | 1.013 (0.751–1.365) |
0.901 (0.661–1.228) |
44.46 | 40.93 | 1.147 (1.031–1.277) |
1.049 (0.936–1.175) |
| ESRD or CKD Stages 4 and 5 | 8.48 | 8.34 | 1.016 (0.714–1.447) |
1.003 (0.688–1.462) |
54.41 | 54.73 | 1.018 (0.893–1.161) |
1.004 (0.873–1.155) |
| ȃESRD | 8.48 | 11.37 | 0.722 (0.451–1.156) |
0.802 (0.491–1.309) |
57.56 | 60.98 | 0.913 (0.765–1.090) |
0.978 (0.814–1.175) |
| ȃCKD Stages 4 and 5 | 8.77 | 7.48 | 1.199 (0.813–1.768) |
1.138 (0.754–1.719) |
55.12 | 53.47 | 1.090 (0.934–1.272) |
1.039 (0.882–1.225) |
| Malignancy | 4.97 | 4.22 | 1.205 (0.902–1.608) |
1.033 (0.770–1.386) |
34.95 | 33.15 | 1.116 (1.003–1.242) |
1.023 (0.916–1.143) |
| ȃMalignancy without treatment | 4.32 | 3.97 | 1.098 (0.782–1.543) |
0.975 (0.691–1.375) |
31.85 | 31.16 | 1.072 (0.950–1.209) |
1.010 (0.892–1.142) |
| Tricuspid valve disease | 4.73 | 4.12 | 1.150 (0.841–1.573) |
1.024 (0.745–1.408) |
34.66 | 32.87 | 1.113 (1.000–1.24) |
1.044 (0.935–1.167) |
Hazard ratios and odds ratios adjusted using overlapping weights. Confidence Intervals adjusted for multiple comparisons (number of tests = 9). ESRD and CKD Stages 4 or 5 are not mutually exclusive.
aDCSI, adapted Diabetes Complication Severity Index; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; ESRD, end-stage renal disease; HR, hazard ratio; L-VVI, leadless-VVI; OR, odds ratio; TV-VVI, transvenous-VVI.